Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSC-204-A0101 + TSC-202-A0201
- Development stage
- Phase 1
- Lead developer
- TCRx Therapeutics
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TSC-204-A0101 + TSC-202-A0201 is a combination of two autologous, engineered T cell receptor (TCR)-T cell therapies developed by TScan Therapeutics for the treatment of solid tumors. Each component targets a specific cancer-testis antigen presented by different HLA types: - **TSC-204-A0101** targets melanoma-associated antigen 1 (MAGE-A1) in the context of HLA type A*01:01. - **TSC-202-A0201** targets melanoma-associated antigen 4 (MAGE-A4) in the context of HLA type A*02:01. These therapies are part of the "T-Plex" platform, which enables multiplexed administration of customized combinations of high-affinity, naturally occurring TCR-Ts based on tumor target and patient HLA expression. The goal is to overcome tumor heterogeneity and potential immune escape due to loss or variation in target antigens or HLAs. The combination is being evaluated in Phase 1 clinical trials for patients with various solid tumors[4][6][7].
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)MAGE-A4 peptide-HLA-A*02:01 complex
Beyond the preview
Go deeper on TSC-204-A0101 + TSC-202-A0201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSC-204-A0101 + TSC-202-A0201.